with increasing ATD risk sextiles, in conjuction with increasing numbers of ATD patients. At any level of any of the other lipid predictors except CT:HDL, the average age of ATD onset is dependent of the associated CRF. That is, at any level of the other lipd predictors except CT:HDL, a higher associated CRF is asso- ciated with an earlier average age of ATD onset and a lower CRF is asso- ciated with a later average age of ATD onset. Conclusions: Because the CRF, unlike the other lipid predictors, predicts the population at risk of ATD better and better in more and more patients and because the higher risk sextiles of the CRF and CT:HDL predict younger ATD patients, whereas the lower risk sextiles predict older ATD pataients– unlike the other lipid predictors–it is proposed that the CRF is the best lipid predictor. CT:HDL is equally as good as the CRF in predicting the ages of ATD patients, but predicts better and better in fewer and fewer patients and suffers from problems in reproduceability. P1.050 UNDERDIAGNOSIS, UNDERTREATMENT AND CARDIOVASCULAR RISK MISPERCEPTION AMONG INDIVIDUALS WITH SUSPECTED FAMILIAL HYPERCHOLESTEROLEMIA: A BRAZILIAN SURVEY Marcio Bittencourt 2 , Antonio Laurinavicius 2 , Carolina Pereira 2 , Fernando Cesena 2 , Raquel Conceiç~ao 2 , Raul D. Santos 1 . 1 Hospital Albert Einstein and University of Sao Paulo, Sao Paulo, SP, Brazil; 2 Hospital Albert Einstein, Sao Paulo, SP, Brazil Objective: It is widely accepted that Familial Hypercholesterolemia (FH) is currently mishandled in most countries. However, epidemiologic data are still scarce and estimations on prevalence, diagnosis, treatment and con- trol continue to rely predominantly on experts’ opinion. The aim of the present study was to assess the degree of disease awareness, quality of treatment and effective control of suspected FH patients. Methods: From a database of 70,000 Brazilian individuals submitted to routine health evaluation between 2006 and 2016, 1,987 met the inclusion criteria (age  18 years and LDL-C 190mg/dL without statins or 160mg/ dL if on statin therapy). 200 were randomly invited to answer an extensive questionnaire by phone or through e-mail. Baseline clinical and laboratory evaluation, including lipids assessment, was available for all the partici- pants. The structured survey included questions about disease awareness, diagnosis, adherence to treatment, and cardiovascular (CV) risk perception from the patient perspective. Results: Although 97.5% of the sample (mean age: 48±9 years; women: 17%; post-secondary education: 95%; primary prevention: 87.5%) was aware to carry very high cholesterol levels, only 24.5% (N¼49) had ever heard about FH and merely 14% (N¼29) had been previously identiﬁed as possible or probable FH by their healthcare providers. Mean age of FH diagnosis was 35±12 years and only 2.5% (N¼5) performed genetic tests. First degree relatives were summoned or alerted in less than 5% (N¼9) of cases. 39% underwent a diet trial before introducing statin therapy and 37.5% were not on lipid lowering treatment when interviewed. Among those who previously stopped statin therapy, 57% did so by their own choice; 20% by medical advice; while 23% alleged side effects. 152 (76%) and 85 (42.5%) reported positive family history for dyslipidemia and car- diovascular disease, respectively. Only 20% considered themselves at high CV risk and, although almost 30% supposed to know their LDL-C targets, barely one (0.5%) was actually able to mention it. Conclusions: Familial Hypercholesterolemia is still underdiagnosed and uncontrolled in Brazil, even among individuals of high educational level. There is still room for improvement through medical education and pa- tients’ engagement. P1.051 ELEVATED FASTING PLASMA APOB-LIPOPROTEIN REMNANTS ARE ASSOCIATED WITH METS AND PCOS: EARLY CARDIOVASCULAR DISEASE RISK IN ADOLESCENTS Donna F. Vine . University of Alberta, Edmonton, AB, Canada Background: Adolescents with polycystic ovary syndrome (PCOS) have increased incidence of the metabolic syndrome and dyslipidemia associ- ated with early cardiovascular disease (CVD) risk. However, atherogenic apo-B-lipoprotein cholesterol remnants, apo-B48 and apo-B100, and the relationship to the metabolic syndrome and early subclinical CVD risk have not been examined in adolescents with PCOS. Aim: The aim of this study was to determine the fasting and non-fasting concentration of plasma apoB-lipoprotein remnants and the association with features of the metabolic syndrome in adolescents with and without PCOS in a case-control study, and from the population-based Pregnancy cohort in Western Australia (RAINE)-Menstruation in Teenagers Study (MTS). Methods: Metabolic data and fasting and non-fasting plasma lipids and apo-B48 and -B100 were determined in healthy weight and obese adolescent girls with and without PCOS aged 12-17 yrs (n¼45), and fasting plasma apo-B48 and -B100 was determined in the RAINE-MTS Cohort aged 16-17 yrs (n¼204). Results: Obese-control and obese-PCOS groups had 2-fold higher con- centrations of fasting plasma triglycerides, apoB100- and apoB48-lipo- protein remnants compared to healthy-weight controls (P< 0.001). The postprandial or non-fasting response in TG(AUC) and apoB48(AUC) was higher in both obese-controls and obese-PCOS subjects compared with healthy-weight controls (P<0.01), and these were positively correlated with free testosterone (r¼0.38; P<0.001 and r¼0.33; P <0.05, respectively). In the RAINE-MTS Cohort fasting plasma apo-B48, but not apo-B100, was signiﬁcantly elevated in the metabolic syndrome (p<0.032), and was positively correlated with plasma triglycerides (p<0.0001, r 2 ¼0.179) in all adolescent girls. The incidence of the metabolic syndrome was increased 3-fold in girls with PCOS (37.5%) compared to non-PCOS (13.7%), and the metabolic syndrome was associated with a 1.82 ug/ml in fasting plasma apoB48-remnants compared to controls (p<0.01). Conclusion: Elevated plasma apolipoprotein-B48 and TG is highly associ- ated with the MetS in adolescent girls, and in girls with PCOS there is an increased incidence of the MetS predisposing them to early car- diometabolic and global CVD risk. P1.052 THE ROLE OF SERUM TRIGLYCERIDE AND NON HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PREDICTING CARDIOVASCULAR RISK Andi Ahwal Rauf , Rizna A. Said, Yusran A. Fitrah, Bumi Z. Herman. Hasanuddin University, Makassar, Indonesia Objective: Cardiovascular disease (CVD) is a signiﬁcant cause of death worldwide, especially in developed countries, such as Indonesia. Non-High Density Lipoprotein Cholesterol (Non-HDLC) is an important lipid proﬁle parameter to assess cardiovascular risk that could serve as an additional screening tool along with Low Density Lipoprotein Cholesterol (LDLC) and Triglyceride (TG). Although this parameter has a lot of advantages, it is rarely used by general practitioners in lipid proﬁle assessment. Methods: This cross sectional study was carried out from 730 patients during January to December 2017. The relationship between serum lipids and the risk for cardiovascular disease was determined by dividing the lipid proﬁles into two groups stratiﬁed by the levels of non-HDLC and LDLC. The cut-off value was 1.13 mmol/L for TG. Results: Analysis of 730 lipid proﬁles showed that 506 (69.32%) patients had triglyceride levels above 1.13 mmol/L. Of these, 6.99% of the samples showed high non-HDLC with normal LDLC while 3.15% showed high LDLC with normal non-HDLC. Total serum Triglycerides and the TG/HDL ratio were signiﬁcantly higher in the high NoneHDLC groups for both males and females. Conclusions: TG and Non-HDLC are more recommended than LDLC as predictors of cardiovascular disease risk factors based on this study. Therefore, it is recommended that Non-HDLC be added as part of lipid proﬁle parameter and TG/HDL ratio be recognized as a possible important indicator of cardiovascular risk Abstracts / Atherosclerosis Supplements 32 (2018) 1e162 48